(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 February 2022 (24.02.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/038226 A1

(51) International Patent Classification:

A61K 31/7048 (2006.01)	*A61K 47/26* (2006.01)
A61K 9/08 (2006.01)	*A61K 47/02* (2006.01)
A61K 9/00 (2006.01)	*A61P 31/00* (2006.01)
A61K 47/14 (2017.01)	*A61P 1/16* (2006.01)
A61K 47/10 (2017.01)	*A61K 47/12* (2006.01)

(21) International Application Number:
PCT/EP2021/073034

(22) International Filing Date:
19 August 2021 (19.08.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

2012956.5	19 August 2020 (19.08.2020)	GB
2012954.0	19 August 2020 (19.08.2020)	GB

(71) Applicants: **MUNDIPHARMA INTERNATIONAL CORPORATION LIMITED**; 14 Par-la-ville Road P O Box HM 2332, HM JX Hamilton (BM). **PURDUE PHARMA L.P.** [US/US]; One Stamford Forum 201 Tresser Boulevard, Stamford, Connecticut 06901 (US).

(72) Inventors; and
(71) Applicants: **GUGGI, Davide** [IT/GB]; c/o Mundipharma International Limited, Unit 194, Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire CB4 0AB (GB). **MONTES VÁZQUEZ, Anna** [ES/GB]; c/o Mundipharma International Limited, Unit 194, Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire CB4 0AB (GB). **MARTÍNEZ RUBIO, Javier** [ES/GB]; c/o Mundipharma International Limited, Unit 194, Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire CB4 0AB (GB).

(74) Agent: **KUTTENKEULER, David**; Boehmert & Boehmert Anwaltspartnerschaft mbB, Pettenkoferstrasse 22, 80336 Munich (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2022/038226 A1

(54) Title: ETOPOSIDE TONIRIBATE FORMULATION

(57) Abstract: A liquid pharmaceutical formulation comprising etoposide toniribate; a polysorbate; and ethanol. A method of preparing an infusion solution comprising diluting said liquid pharmaceutical formulation. Said composition or solution for use in treating cancer in a patient in need thereof.